Anti-Mouse CD45.2 [Clone 104.2] — Purified in vivo PLATINUM™ Functional Grade

Clone 104.2 is a monoclonal antibody that targets the CD45.2 alloantigen, commonly used in mouse models expressing this antigen, such as C57BL/6 and BALB/c strains. The common in vivo applications of clone 104.2 include:

• Flow Cytometry: Used as a leukocyte marker to identify and analyze immune cells.
• Immunofluorescence Microscopy: Utilized for detecting CD45.2 expression in mouse tissues.
• Immunoprecipitation: Helps in studying protein interactions involving CD45.2.
• Blocking B Cell Responses: Demonstrated to block B cell responses in vitro and reduce serum autoantibody concentrations in vivo, particularly in models like SLE-prone mice.
• In Vivo Labeling: Used for labeling immune cells, such as airway immune cells, to study their dynamics.

Overall, clone 104.2 is a versatile tool in immunology research for identifying and manipulating immune cells in mouse models.

Commonly Used Antibodies and Proteins Paired with CD45.2 Antibody (clone 104.2)

The CD45.2 monoclonal antibody (clone 104.2) is widely used in mouse immunology research, particularly for identifying and sorting hematopoietic cells via flow cytometry. When used in experimental panels, 104.2 is often paired with other antibodies and protein markers to achieve multi-parameter analysis of immune cell subsets. Here are some of the most common and contextually relevant pairings found in the literature or implied by standard practices.

Common Antibody Pairings

• Isotype Controls: As part of standard flow cytometry protocols, 104.2 is often used alongside an isotype control antibody (e.g., PE/Cyanine5 Mouse IgG2a, κ Isotype Control [C1.18.4]) to confirm the specificity of staining and rule out non-specific binding.
• Lineage Markers: In studies of hematopoietic stem cells and immune cell populations, CD45.2 (clone 104.2) is frequently combined with antibodies against lineage markers such as CD3 (T cells), CD19 (B cells), CD11b (myeloid cells), Gr-1 (neutrophils), and B220 (B cells), especially in bone marrow or peripheral blood analysis.
• Activation/Maturation Markers: Co-staining with markers like CD44, CD62L, CD25, CD69, and MHC II is common in immune phenotyping and functional studies to assess cell activation or differentiation status.
• Co-stimulatory/Inhibitory Molecules: Antibodies against proteins such as CD28, CTLA-4, PD-1, and CD152 are often included in panels with CD45.2 for functional immune profiling.
• Cytokine Receptors: Markers like IL-7Rα (CD127) and IL-2Rα (CD25) are used to further define T-cell subsets (e.g., naïve, memory, regulatory T cells).
• Cell Cycle and Proliferation Markers: In proliferation or transplantation studies, CD45.2 is sometimes paired with Ki-67 or BrdU to assess dividing cells.

Commonly Targeted Proteins (Ligands/Receptors)

CD45.2 is a protein tyrosine phosphatase (PTPRC, Ly5.2) expressed on all hematopoietic cells except mature erythrocytes and platelets. Its ligands and interacting proteins include:

• Galectin-1: A lectin that binds to CD45 and modulates T-cell receptor (TCR) signaling.
• CD2, CD3, CD4, TCR: Coreceptors and signaling molecules involved in T-cell activation.
• CD22, Thy-1: Additional surface markers on lymphocytes with roles in cell signaling and adhesion.

These molecules are often studied in conjunction with CD45.2 in functional and signaling experiments.

Typical Experimental Contexts

Flow Cytometry Panels: CD45.2 (104.2) is almost always part of a larger antibody panel. For example, a basic lymphoid panel might include CD45.2, CD3, CD19, and CD11b, while a myeloid panel might pair CD45.2 with Gr-1, CD11b, and F4/80. The exact combination depends on the research question.

Transplantation Studies: In hematopoietic stem cell transplantation, CD45.2 (donor) is contrasted with CD45.1 (recipient) to track engraftment, often alongside lineage and progenitor markers (e.g., Sca-1, c-Kit).

Signal Transduction Studies: Investigations into TCR or BCR signaling often include CD45.2 to identify relevant cell populations, alongside phospho-specific antibodies (e.g., p-ERK, p-AKT) to assess downstream signaling.

Summary Table

Conclusion

CD45.2 (clone 104.2) is rarely used in isolation; it is typically part of a multi-parameter flow cytometry panel. Pairings depend heavily on the biological question but most commonly include lineage, activation, co-stimulatory, cytokine receptor, and proliferation markers, as well as proteins involved in signal transduction and ligand-receptor interactions. Isotype controls are always recommended to ensure specificity. For detailed experimental design, researchers should consult recent literature in their specific field of interest.

Based on the available information, clone 104.2 refers to a monoclonal antibody that targets mouse CD45.2, but the search results primarily provide product information rather than scientific literature citations showing key research findings.

Clone 104.2 Antibody Characteristics

Clone 104.2 is a mouse IgG2a monoclonal antibody that recognizes CD45.2, a 180-240 kDa member of the protein tyrosine phosphatase family. CD45.2 is an alloantigen of CD45 expressed on all hematopoietic cells except mature erythrocytes and platelets, and it plays a role in T cell receptor (TCR) and B cell receptor (BCR) signal transduction.

Strain Specificity

The antibody shows specific reactivity patterns across mouse strains. It recognizes CD45.2 in strains including C57BL/6, CBA, 129, A, AKR, C58, DBA/1, DBA/2, BALB/c, and C3H/He. Conversely, it does not react with leukocytes from CD45.1-expressing strains such as DA, SJL/J, RIII, and STS/A.

Functional Applications

The 104.2 antibody has demonstrated functional effects in experimental settings. It has been shown to block B cell responses in vitro and reduce serum autoantibody concentration in vivo in SLE-prone mice. This suggests potential applications in studying autoimmune conditions and B cell biology.

However, the search results do not contain specific citations from peer-reviewed scientific literature detailing key research findings using clone 104.2. The information available is primarily from commercial antibody suppliers rather than research publications that would document experimental outcomes, methodologies, or significant discoveries made using this clone.

Currently, there is limited specific information available on the dosing regimens of clone 104.2 across different mouse models. However, general principles of antibody dosing in mouse models can be applied. Clone 104.2 is a monoclonal antibody that reacts with mouse CD45.2, which is expressed on leukocytes of certain mouse strains. It is often used for cell depletion or modulation in immunology studies.

General Principles of Antibody Dosing in Mouse Models

• Standard Dose Range: Typical antibody doses in mouse models range from 100 to 500 μg per mouse, depending on the target and application.
• Route of Administration: Intraperitoneal injection is commonly used, offering a straightforward method for delivering antibodies to the peritoneal cavity.
• Dosing Schedule: Frequencies can vary, but common schedules include every 3-4 days for checkpoint blockade antibodies like anti-PD-1.
• Application-Specific Dosing: For clone 104.2, dosing might be adjusted based on the specific application, such as flow cytometry or in vivo depletion.

Specifics for Clone 104.2

While specific dosing regimens for clone 104.2 are not detailed in the available search results, this antibody has been used to block B cell responses in vitro and reduce serum autoantibody levels in vivo in SLE-prone mice. For precise dosing, researchers would typically consult peer-reviewed literature or established protocols for similar applications.

Recommendations

1. Consult Literature: Look for studies using clone 104.2 in similar mouse models to establish a baseline dose.
2. Adjust Based on Model: Consider the specific requirements of your mouse model, such as the target cell type and the experimental aim.
3. Pilot Studies: Perform pilot experiments to determine the optimal dose for your specific application.

In summary, while specific dosing regimens for clone 104.2 are not explicitly detailed, using established protocols and adjusting based on experimental needs can help guide dosing decisions.